Figure 3

Survival and ANDV RNA levels in Alp-PcIgG-ANDV treated Syrian hamsters. Syrian hamsters were infected with 154 FFU of ANDV and treated with either PBS, purified naïve alpaca IgG, or ANDV-specific Alp-PcIgG at different time points post-infection. (A) Survival curve following ANDV infection and indicated treatment on days + 1/ + 3 with respect to ANDV challenge. (B) Viral RNA levels in blood and tissues of treated or mock-treated (days + 1/ + 3, with respect to challenge), ANDV infected hamsters. (C) Survival of hamsters treated at extended time points (days + 2/ + 4 or days + 3/ + 5, with respect to ANDV challenge) with ANDV-specific Alp-PcIgG or PBS. (D) Viral RNA levels in the blood and tissues of treated (days + 2/ + 4 or days + 3/ + 5, with respect to ANDV challenge) and untreated ANDV infected hamsters. For (A) and (C), n = 6 per group. For B and D, n = 3 per group euthanized on the day post-infection when control animal met the criteria for euthanasia. For (A) and (C), significance assessed by Log-rank (Mantel-Cox) test. For (B) and (D), significance was assessed by two-way analysis of variance. ** = p < 0.01, *** = p < 0.001.